A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hanson's Yeast) in Chinese Women Aged 9-45 Years

Conditions:   HPV Infection;   HPV-Related Cervical Carcinoma Interventions:   Biological: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha);   Biological: Placebo Sponsors:   National Vaccine and Serum Institute, China;   Chengdu Institute of Biological Products Co.,Ltd.;   Simoon Record Pharma Information Consulting Co., Ltd;   Guangxi Center for Disease Control and Prevention;   Beijing Kantorico Statistical Technology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials